Rapid Defense's immunotherapies are designed for conditions where immune dysfunction drives disease progression:
● Non-Small Cell Lung Cancer (NSCLC): A leading cause of cancer mortality globally. ImmunoFolate™ supports immune targeting and tumor response.
● Acute Respiratory Distress Syndrome (ARDS) is common in intensive care. ImmunoPterin seeks to control systemic inflammation and lung injury.
● Sepsis: A life-threatening condition involving immune overreaction. Our therapy supports immune modulation.
● Pneumonia: Severe lung infections often escalate into ARDS; ImmunoFolate™ aids in immune response regulation.
● Severe Trauma: Immune dysfunction from trauma leads to secondary complications, which our therapy seeks to mitigate.
Our therapies are supported by peer-reviewed research, preclinical data, and clinical trial insights.
Highlights:
● ImmunoFolate™ has shown promise in reducing immune escape mechanisms such as indoleamine 2,3 dioxygenase, in NSCLC.
● ImmunoPterin demonstrated cytokine modulation and improved immune response in preclinical ARDS models.
● Mechanism of action studies are available for download at http://linkedin.com/in/phillip-moheno-phd-3852214.
● Research-Driven Innovation: Therapies developed from immunological insights
● Targeted Immune Modulation: Not symptom suppression, but immune reprogramming
● Clinical Expertise: Led by a team of experienced immunologists and medical scientists
● Transparent & Ethical: Committed to safety, data transparency, and regulatory compliance
ImmunoFolate™ is based on the hypothesis that pterin and folate derivatives can restore immune homeostasis by modulating cytokines like IL-6, IL-10, IL-12, IFN-γ, and TGF-β; and IDO (Indoleamine 2,3 dioxygenase) impacting immune surveillance, tumor evasion, and inflammation resolution.
We are preparing a Phase 1/2 clinical trials of ImmunoFolate™for patients with ARDS and non-small cell lung cancer and metastatic colorectal cancer.
✅ Trial protocol developed
✅ Seeking FDA IND clearance
✅ Now raising $10M in seed funding
Rapid Defense Inc. is a biopharmaceutical company committed to developing innovative immunotherapy solutions that enhance the immune system's capabilities in combating diseases. Our flagship product, ImmunoFolate, is designed to enhance and modulate immune responses.